VX-11e | CAS#896720-20-0 | ERK2 inhibitor

MedKoo Cat#: 562789 | Name: VX-11e

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VX-11e is a selective and potent inhibitor of ERK1/2 (extracellular signal-regulated kinases 1 and 2), key components of the MAPK (mitogen-activated protein kinase) pathway involved in cell proliferation, survival, and differentiation. By inhibiting ERK1/2 activity, VX-11e disrupts oncogenic signaling in RAS- and RAF-mutated cancers, which often rely on hyperactive MAPK signaling for uncontrolled growth. Its high selectivity for ERK1/2 minimizes off-target effects, making it a promising candidate for targeted cancer therapy.

Chemical Structure

VX-11e

CAS#896720-20-0

Theoretical Analysis

MedKoo Cat#: 562789

Name: VX-11e

CAS#: 896720-20-0

Chemical Formula: C24H20Cl2FN5O2

Exact Mass: 499.0978

Molecular Weight: 500.35

Elemental Analysis: C, 57.61; H, 4.03; Cl, 14.17; F, 3.80; N, 14.00; O, 6.40

Price and Availability

Size	Price	Availability
100mg	USD 950.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 3,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

VX-11e; VX 11e; VX11e; VTX-11e; VTX11e; VTX 11e; ERK-11e; ERK 11e; ERK11e;

IUPAC/Chemical Name

4-[2-(2-Chloro-4-fluoroanilino)-5-methylpyrimidin-4-yl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide

InChi Key

WUTVMXLIGHTZJC-OAQYLSRUSA-N

InChi Code

InChI=1S/C24H20Cl2FN5O2/c1-13-10-29-24(31-19-6-5-17(27)9-18(19)26)32-22(13)15-8-20(28-11-15)23(34)30-21(12-33)14-3-2-4-16(25)7-14/h2-11,21,28,33H,12H2,1H3,(H,30,34)(H,29,31,32)/t21-/m1/s1

SMILES Code

O=C(C1=CC(C2=NC(NC3=CC=C(F)C=C3Cl)=NC=C2C)=CN1)N[C@@H](C4=CC=CC(Cl)=C4)CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 500.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhang X, Rameika N, Zhong L, Rendo V, Veanes M, Kundu S, Nuciforo S, Dupuis J, Al Azhar M, Tsiara I, Seeburger P, Al Nassralla S, Ljungström V, Svensson R, Stoimenov I, Artursson P, Heim MH, Globisch D, Sjöblom T. Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib. EBioMedicine. 2024 Nov;109:105368. doi: 10.1016/j.ebiom.2024.105368. Epub 2024 Oct 4. PMID: 39368455; PMCID: PMC11490764. 2: Han Y, Wang J, Zhang J, Zheng X, Jiang Y, Liu W, Li W. VX-702 Ameliorates the Severity of Sepsis-Associated Acute Kidney Injury by Downregulating Inflammatory Factors in Macrophages. J Inflamm Res. 2024 Jun 21;17:4037-4054. doi: 10.2147/JIR.S464018. PMID: 38919509; PMCID: PMC11198005. 3: Fortier SM, Walker NM, Penke LR, Baas JD, Shen Q, Speth JM, Huang SK, Zemans RL, Bennett AM, Peters-Golden M. MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution. J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. PMID: 38512415; PMCID: PMC11093610. 4: Espitia GJ, Arenas NE, Gutiérrez-Castañeda LD, Guerrero MI. Bioinformatic approach for repurposing immunomodulatory drugs for lepromatous leprosy. Int J Mycobacteriol. 2023 Oct-Dec;12(4):388-393. doi: 10.4103/ijmy.ijmy_105_23. PMID: 38149532. 5: Faist A, Schloer S, Mecate-Zambrano A, Janowski J, Schreiber A, Boergeling Y, Conrad BCG, Kumar S, Toebben L, Schughart K, Baumgardt M, Kessler M, Hoenzke K, Hocke A, Trautmann M, Hartmann W, Kato H, Rescher U, Christersson A, Kuehn J, Mellmann A, Wolff T, Kuempers P, Rovas A, Wiewrodt R, Wiebe K, Barth P, Ludwig S, Brunotte L. Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. Antiviral Res. 2023 Jan;209:105475. doi: 10.1016/j.antiviral.2022.105475. Epub 2022 Nov 21. PMID: 36423831; PMCID: PMC9677559. 6: Zhao J, Shi X, Dong C, Liu R, Su L, Cao C. 5-fluorouracil suppresses stem cell-like properties by inhibiting p38 in pancreatic cancer cell line PANC-1. Folia Histochem Cytobiol. 2022;60(1):55-65. doi: 10.5603/FHC.a2022.0004. Epub 2022 Feb 1. PMID: 35103981. 7: Hu YH, Zhou X, Jiang XX, Zhang GR, Shi ZC, Ji W, Ma XF, Luo ZL, Wei KJ. Molecular characterization, expression analysis and function identification of Pf_TNF-α and its two receptors Pf_TNFR1 and Pf_TNFR2 in yellow catfish (Pelteobagrus fulvidraco). Int J Biol Macromol. 2021 Aug 31;185:176-193. doi: 10.1016/j.ijbiomac.2021.06.090. Epub 2021 Jun 16. PMID: 34144067. 8: Skripchenko A, Gelderman MP, Vostal JG. P38 mitogen activated protein kinase inhibitor improves platelet in vitro parameters and in vivo survival in a SCID mouse model of transfusion for platelets stored at cold or temperature cycled conditions for 14 days. PLoS One. 2021 May 11;16(5):e0250120. doi: 10.1371/journal.pone.0250120. PMID: 33974660; PMCID: PMC8112650. 9: Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine- resistant Breast Cancer. Clin Cancer Res. 2021 May 1;27(9):2648-2662. doi: 10.1158/1078-0432.CCR-20-2961. Epub 2021 Feb 4. PMID: 33542078; PMCID: PMC8653766. 10: Spivack K, Muzzelo C, Hall M, Warga E, Neely C, Slepian H, Cunningham A, Tucker M, Elmer J. Enhancement of transgene expression by the β-catenin inhibitor iCRT14. Plasmid. 2021 Mar;114:102556. doi: 10.1016/j.plasmid.2021.102556. Epub 2021 Jan 17. PMID: 33472046. 11: Huang C, Wang XL, Qi FF, Pang ZL. Berberine inhibits epithelial-mesenchymal transition and promotes apoptosis of tumour-associated fibroblast-induced colonic epithelial cells through regulation of TGF-β signalling. J Cell Commun Signal. 2020 Mar;14(1):53-66. doi: 10.1007/s12079-019-00525-7. Epub 2019 Aug 9. PMID: 31399854; PMCID: PMC7176772. 12: Huang C, Wu XF, Wang XL. Trichostatin a inhibits phenotypic transition and induces apoptosis of the TAF-treated normal colonic epithelial cells through regulation of TGF-β pathway. Int J Biochem Cell Biol. 2019 Sep;114:105565. doi: 10.1016/j.biocel.2019.105565. Epub 2019 Jul 3. PMID: 31278993. 13: Jin X, Yu Y, Zou Q, Wang M, Cui Y, Xie J, Wang Z. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1. J Cell Biochem. 2019 Apr;120(4):5880-5888. doi: 10.1002/jcb.27873. Epub 2018 Oct 14. Retraction in: J Cell Biochem. 2021 Nov;122 Suppl 1:S34. doi: 10.1002/jcb.29993. PMID: 30317672. 14: Blair TA, Moore SF, Walsh TG, Hutchinson JL, Durrant TN, Anderson KE, Poole AW, Hers I. Phosphoinositide 3-kinase p110α negatively regulates thrombopoietin- mediated platelet activation and thrombus formation. Cell Signal. 2018 Oct;50:111-120. doi: 10.1016/j.cellsig.2018.05.005. Epub 2018 May 21. PMID: 29793021. 15: Matsushita T, Date M, Kano M, Mizumaki K, Tennichi M, Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease. Am J Pathol. 2017 Apr;187(4):841-850. doi: 10.1016/j.ajpath.2016.12.016. Epub 2017 Feb 9. PMID: 28189565. 16: Wagner SJ, Skripchenko A, Seetharaman S, Kurtz J. Amelioration of lesions associated with 24-hour suboptimal platelet storage at 16 °C by a p38MAPK inhibitor, VX-702. Vox Sang. 2015 Apr;108(3):226-32. doi: 10.1111/vox.12221. Epub 2014 Dec 4. PMID: 25471280. 17: Skripchenko A, Awatefe H, Thompson-Montgomery D, Myrup A, Turgeon A, Wagner SJ. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS One. 2013 Aug 13;8(8):e70732. doi: 10.1371/journal.pone.0070732. PMID: 23967093; PMCID: PMC3742641. 18: Tamhane M, Chakilam AR, Jayaraj A, Thakkar V, Taft DR. Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Dev Ind Pharm. 2010 Mar;36(3):315-22. doi: 10.3109/03639040903154200. PMID: 20170280. 19: Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol. 2010 May;22(3):330-5. doi: 10.1097/BOR.0b013e3283378e6f. PMID: 20164774. 20: Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906. PMID: 19950901.